Pr. Yves Lévy has created the Vaccine Research Institute (VRI). The VRI’s structure strengthens the links between basic, translational research, patients’ associations and the socioeconomic world to develop vaccines against (re)-emerging pathogens.
The VRI includes a large network of teams In France, Europe and US gathering key international opinion leaders through a unique collaborative network and with a central strategic plan.
In his career Pr. Yves Lévy has moved up to ten candidate vaccines until clinical development through academic or public/ industrial partnership.
Through this expertise, Pr. Y. Lévy has been instrumental in designing and implementing early proof-of-concept and Phase 3 clinical trials in France, Europe and internationally. Y. Lévy has published more than 400 original papers.
He is co founder and Chief Scientific and Medical Officer of LinKinVax, a spin-off of the VRI created in 2020 to develop targeted immunotherapies against infectious diseases and cancer.